These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 8154643

  • 1. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group.
    De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP.
    Ann Intern Med; 1994 May 15; 120(10):834-44. PubMed ID: 8154643
    [Abstract] [Full Text] [Related]

  • 2. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
    Marie JP, Marjanovic Z, Vekhoff A, Bouvet A, Chast F, Levy V, Baudard M, Legrand O, Rio B, Delmer A, Zittoun R.
    Support Care Cancer; 1999 Mar 15; 7(2):89-94. PubMed ID: 10089089
    [Abstract] [Full Text] [Related]

  • 3. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial.
    Peacock JE, Herrington DA, Wade JC, Lazarus HM, Reed MD, Sinclair JW, Haverstock DC, Kowalsky SF, Hurd DD, Cushing DA, Harman CP, Donowitz GR.
    Ann Intern Med; 2002 Jul 16; 137(2):77-87. PubMed ID: 12118962
    [Abstract] [Full Text] [Related]

  • 4. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP.
    Antimicrob Agents Chemother; 1995 Feb 16; 39(2):445-52. PubMed ID: 7726513
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.
    Feliu J, Artal A, González Barón M, Berrocal A, Chacón I, García de Paredes ML, Espinosa E, Ordóñez A, Zamora P, Montero JM.
    Antimicrob Agents Chemother; 1992 Dec 16; 36(12):2816-20. PubMed ID: 1482151
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group.
    Sieger B, Berman SJ, Geckler RW, Farkas SA.
    Crit Care Med; 1997 Oct 16; 25(10):1663-70. PubMed ID: 9377880
    [Abstract] [Full Text] [Related]

  • 17. Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children.
    Jacobs RF, Vats TS, Pappa KA, Chaudhary S, Kletzel M, Becton DL.
    Infection; 1993 Oct 16; 21(4):223-8. PubMed ID: 8225625
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.